2-((tert-Butoxycarbonyl)amino)-3-(pyridin-2-yl)propanoic acid, 95%, 1g

Ethoxydiphenylphosphine, 95.0%, 5g

4-(4-Bromophenyl)butan-1-ol, 95.0%, 1g

1-(4-Fluoro-benzenesulfonyl)-piperidine-3-carboxylic acid, 95.0%, 250mg

4-Methyltetrahydro-2H-thiopyran-4-ol, 97.0%, 10g

4-Nitrobenzenethiol>95.0%(GC)(T)5g

2'-Deoxythymidine-5'-monophosphate disodium salt, 95.0%, 100mg

Glycylglycine, 250 g

2-Aminopyrimidine-5-carbaldehyde, 95.0%, 25g

6-Bromo-7-methylquinoxaline, 97%, 5g

Long working distance plan phase 4x/0.13 IOS objective, working distance 10.75 mm

Cu-TMEDA catalyst, 97%, 1g

a-METHYL P-METHOXY CINNAMIC ALDEHYDE, 97.0%, 1g